Saracatinib and Alcohol Drinking

• Status: Completed
• Trial end date: 2019-06-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of the study medication, saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. The investigators hypothesize that saracatinib will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Treatments: Saracatinib

Criteria

Inclusion Criteria:

• Ages 21-50

• Able to read English at 6th grade level or higher and to complete study evaluations

• Regular alcohol drinker

Exclusion Criteria:

• Individuals who are seeking alcohol treatment

• Medical conditions that would contraindicate the use of saracatinib

• Regular use of other substances